These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31618395)

  • 21. Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated.
    Allegretti JR; Canakis A; McClure E; Marcus J; Norton BA; Hamilton MJ; Winter RW; De Silva PS; Friedman S; Korzenik JR
    Inflamm Bowel Dis; 2021 Nov; 27(12):2031-2033. PubMed ID: 34142700
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
    Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to infliximab is related to disease duration in paediatric Crohn's disease.
    Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
    Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
    Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
    Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
    Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice.
    Cadahia V; García-Carbonero A; Vivas S; Fuentes D; Niño P; Rebollo P; Rodrigo L
    Rev Esp Enferm Dig; 2004 Jun; 96(6):369-74; 374-8. PubMed ID: 15230666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid use is associated with decreased quality of life in patients with Crohn's disease.
    Sanford D; Thornley P; Teriaky A; Chande N; Gregor J
    Saudi J Gastroenterol; 2014; 20(3):182-7. PubMed ID: 24976282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
    Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: Retrospective, multicenter studies.
    Iwańczak BM; Ryżko J; Jankowski P; Sładek M; Wasilewska A; Szczepanik M; Sienkiewicz E; Szaflarska-Popławska A; Więcek S; Czaja-Bulsa G; Korczowski B; Maślana J; Iwańczak F; Kacperska M
    Adv Clin Exp Med; 2017; 26(1):51-56. PubMed ID: 28397432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.